Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035148.xml
Download PDF
Schlaf 2017; 06(01): 14-19
DOI: 10.1055/s-0038-1626155
DOI: 10.1055/s-0038-1626155
Review
Restless-Legs- Syndrom im höheren Lebensalter
Diagnostik und TherapieFurther Information
Publication History
Publication Date:
12 February 2018 (online)
Das Restless-Legs-Syndrom (RLS) zeigt bei älteren Menschen eine hohe Prävalenz. Dennoch ist die Anamnese und Diagnostik in dieser Altersgruppe schwierig. Die Therapie muss insbesondere auch die Grunderkrankungen berücksichtigen, da durch diese selbst oder die verordnete Medikation ein sekundäres RLS ausgelöst werden kann. Da ältere Menschen u.U. schon länger bezüglich eines RLS behandelt werden, wird in diesem Artikel auch auf das Problem der Augmentation eingegangen.
-
Literatur
- 1 Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisir J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003; 4: 101-119.
- 2 Allen RP, Walters AS, Montplaisir J. et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005; 165: 1286-1292
- 3 Bogan RK. From bench to bedside: an overview of rotigotine for the treatment of restless legs syndrome. Clin Ther 2014; 36: 436-455.
- 4 Braun F, Brikkötter PT. Rückgang der Nierenfunktion im Alter. Z Gerontol Geriat 2016; 49: 469-476.
- 5 Crillo DJ, Wallace RB. Restless legs syndrome and functional limitations among American elders in the Health and Retirement Study. BMC Geriatrics 2012; 12: 39.
- 6 Evstatiev R, Alexeeva O, Bokemeyer B. et al. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11 (03) 269-277.
- 7 García-Borreguero D, Allen RP, Kohnen R. et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med 2007; 8: 520-530.
- 8 García-Borreguero D, Grunstein R, Sridhar G. et al. A 52-week open-label study of the long-term safety of ropinorole in patients with restless legs syndrome. Sleep Med 2007; 8: 742-752.
- 9 García-Borreguero D, Stillman P, Benes H. et al. Algorithms for the diagnosis and treatment of restless legs syndrome in primary care. BMC Neurol 2011; 11: 28.
- 10 Fulda S. Gender differences in the prevalence of restless legs syndrome/Willis-Ekbom disease. Somnologie 2013; 17: 246-251.
- 11 Gerhard R, Bosse A, Uzun D. et al. Lebensqualität beim Restless-Legs-Syndrom: Einfluss von Tagesschläfrigkeit und Fatigue. Med Klin 2005; 100: 704-970.
- 12 Henning W, Walters AS, Allen RP. et al. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med 2004; 5: 237-246.
- 13 Högl B, García-Borreguero D, Kohnen R, Ferini-Strambi L. et al. Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study. J Neurol 2010; 257: 230-237.
- 14 Högl B, García-Borreguero D, Trenkwalder C. et al. Efficacy and augmentation during 6 months of double-blind pramipexole for restless legs syndrome. Sleep Med 2011; 12 (04) 351-360.
- 15 Jager KJ, van Dijk PCW, Dekker FW. et al. The epidemic of aging in renal replacement therapy: an update on elderly patients and their outcomes. Clin Nephrol 2003; 60: 352-360.
- 16 Kotterba S. Lösungsansätze für die Augmentation beim Restless-Legs- Syndrom. DNP 2015; 16: 36-43.
- 17 Lipford MC, Silber MH. Long-term use of pramipexole in the management of restless legs syndrome. Sleep Med 2012; 13 (10) 1280-1285.
- 18 Mackie S, Winkelmann JW. Long-Term Treatment of Restless legs syndrome (RLS): an approach to management of worsening symptoms, loss of efficacy, and augmentation. CNS Drugs 2015; 29: 351-357.
- 19 Montplaisir J, Allen RP, Walters A, Ferini-Strambi L. Restless Legs syndrome and periodic limb movements during sleep. In: Kryger MH, Roth T, Dement WC. (eds) Principles and practice of sleep medicine. St. Louis: Elsevier; 5. ed. 2011: 1027-1103.
- 20 O’Keeffe Sh. Secondary causes of restless legs syndrome in older people. Age and Ageing 2005; 34: 349-352.
- 21 Ponokowski P, van Veldhuisen DJ, Comin-Colt J. et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2015; 36: 657-668.
- 22 Rose KM, Beck C, Tsai P. et al. Sleep disturbances and nocturnal agitation behaviors in older adults with dementia. Sleep 2011; 34 (06) 779-786.
- 23 Schaeffner ES, Ebert N, Delanaye P. et al. Two novel equations to estimate kidney function in persons aged 70 years or older. Ann Intern Med 2012; 157: 471-481.
- 24 Stiasny-Kolster K. Medikamentöse Therapie des Restless-legs-Syndroms. Somnologie 2013; 17: 252-258.
- 25 Trenkwalder C. Restless-Legs-Syndrom (RLS) und Periodic Limb Movement Disorder (PLMD) Aus. Diener Hans-Christoph, Weimar Christian. (Hrsg.): Leitlinien für Diagnostik und Therapie in der Neurologie, Herausgegeben von der Kommission „Leitlinien“ der Deutschen Gesellschaft für Neurologie. Stuttgart: Thieme Verlag; 2012
- 26 Trenkwalder C, Beneš H, Grote L. et al. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol 2013; 12 (12) 1141-1150.
- 27 Walters AS, LeBrocq C, Dhar A. et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003; 4: 121-132.